Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 5
1986 6
1987 7
1988 7
1989 4
1990 5
1991 7
1992 1
1993 6
1994 7
1995 3
1996 6
1997 11
1998 4
1999 7
2000 3
2001 9
2002 8
2003 8
2004 14
2005 16
2006 7
2007 13
2008 12
2009 16
2010 13
2011 19
2012 14
2013 23
2014 23
2015 18
2016 14
2017 25
2018 36
2019 23
2020 35
2021 51
2022 36
2023 17
2024 21
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

514 results

Results by year

Filters applied: . Clear all
Page 1
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Wolf J, et al. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. N Engl J Med. 2020. PMID: 32877583 Clinical Trial.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: ardizzoni a. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Dingemans AC, et al. Among authors: ardizzoni a. Ann Oncol. 2021 Jul;32(7):839-853. doi: 10.1016/j.annonc.2021.03.207. Epub 2021 Apr 20. Ann Oncol. 2021. PMID: 33864941 Free PMC article. No abstract available.
Regolazione del prezzo e rimborso dei farmaci: comparatori, endpoint e ruolo della costo-efficacia.
Jommi C, Apolone G, Scroccaro G, Acciai V, Addis A, Ardizzoni A, Bernardini R, Bortolami A, Brigido A, Buzzetti G, Canonico PL, Caprari F, Centanni S, Cernetti C, Cicchetti A, Corsico G, Damele F, de Braud F, Manurita S, Mennini FS, Olivi I, Parretta F, Pippo L, Pulimeno S, Riccaboni M, Rossi G, Saleri C, Sinibaldi A, Spandonaro F, Stefenoni C, Visentin E, Viale P, Zapparelli G, Popoli P. Jommi C, et al. Among authors: ardizzoni a. Glob Reg Health Technol Assess. 2022 Sep 28;9:99-104. doi: 10.33393/grhta.2022.2475. eCollection 2022 Jan-Dec. Glob Reg Health Technol Assess. 2022. PMID: 36628317 Free PMC article. Italian.
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese TE, van Laarhoven HWM, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshof MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs CT, Slingerland M, Voncken FEM, Hartgrink H, Creemers GJ, van der Sangen MJC, Nieuwenhuijzen G, Berbee M, Verheij M, Wijnhoven B, Beerepoot LV, Mohammad NH, Mook S, Ruurda JP, Kolodziejczyk P, Polkowski WP, Wyrwicz L, Alsina M, Pera M, Kanonnikoff TF, Cervantes A, Nilsson M, Monig S, Wagner AD, Guckenberger M, Griffiths EA, Smyth E, Hanna GB, Markar S, Chaudry MA, Hawkins MA, Cheong E, van Hillegersberg R, van Rossum PSN; OMEC collaborators. Kroese TE, et al. Eur J Cancer. 2023 May;185:28-39. doi: 10.1016/j.ejca.2023.02.015. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36947929 Free article.
Real-world data: come possono aiutare a migliorare la qualità dell’assistenza.
Corrao G, Alquati G, Apolone G, Ardizzoni A, Buzzetti G, Canonica GW, Conte P, Crovato E, Damele F, La Vecchia C, Maggioni AP, Mantovani A, Marangi M, Marrocco W, Messori A, Padovani A, Rambaldi A, Ricciardi W, di Meana FR, Spandonaro F, Tozzi V, Mancia G. Corrao G, et al. Among authors: ardizzoni a. Glob Reg Health Technol Assess. 2021 Sep 20;8:134-139. doi: 10.33393/grhta.2021.2286. eCollection 2021 Jan-Dec. Glob Reg Health Technol Assess. 2021. PMID: 36627865 Free PMC article. Italian.
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. Noronha A, et al. Among authors: ardizzoni a. Cancer Discov. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111. Cancer Discov. 2022. PMID: 35895872 Free PMC article.
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.
De Giglio A, Leonetti A, Comito F, Filippini DM, Mollica V, Rihawi K, Peroni M, Mazzaschi G, Ricciotti I, Carosi F, Marchetti A, Rosellini M, Gagliano A, Favorito V, Nobili E, Gelsomino F, Melotti B, Marchese PV, Sperandi F, Di Federico A, Buti S, Perrone F, Massari F, Pantaleo MA, Tiseo M, Ardizzoni A. De Giglio A, et al. Among authors: ardizzoni a. Cancer Immunol Immunother. 2024 Oct 3;73(12):246. doi: 10.1007/s00262-024-03836-w. Cancer Immunol Immunother. 2024. PMID: 39358642 Free PMC article.
514 results